Aim: Xerostomia is an important complication following radiotherapy for head and neck regions producing serious discomfort for patients. Symptomatic treatments for the disease include strict oral hygiene and use of artificial saliva substitutes. The present study compared the efficacy of BioXtra spray and mouthwash in the relief of radiotherapy-induced xerostomia in patients referred to Imam Khomeini Hospital, Tehran University of Medical Sciences.
INTRODUCTION

Radiotherapy (RT) is a treatment modality which is regularly used in the treatment of the head and neck cancers (HNC).
This method destroys tumor cells and also we can expect undesirable effects on normal tissues. 1 Salivary glands are often involved in the head and neck cancer radiotherapy field because of their position. Radiotherapy destroys salivary gland parenchyma and as a result we can expect varying degrees of xerostomia. This phenomenon is usually permanent. Irreversible effects happen at total dosage of greater than 5000 cGy. 2 Saliva has an important protective role against oral disease. It is necessary for lubrication, regulation of the oral cavity flora, teeth demineralization and maintaining soft and hard tissue integrity. 3, 4 Xerostomia, or dryness of the mouth, can cause oral discomfort and pain, difficulty in mastication and swallowing, speech problems, and impairment of taste and smell. It may also lead to an increased risk of dental caries or oral infections. As a result, nutrition intake can be affected with subsequent weight loss. So xerostomia is a major health issue in these patients. 5 Xerostomia can be managed symptomatically. Dental caries and oral infections can be prevented appropriately by strict oral hygiene, fluoride agents and antimicrobials. Systemic sialagogues such as pilocarpine, civemiline, anethole trithione and bethanechol could stimulate salivary secretion from remaining functional salivary acini. These agents have side effects on patients with systemic disease. 6 However, in the absence of functioning tissue, wetting agents or saliva substitutes can be used. These products are mainly based on carboxymethylcellulose (CMC) so these commercials are more viscous than saliva and do not stimulate viscoelastic property of saliva. They also lack the immunological protection of the saliva which is mainly due to lysozyme, lactoferrin, lactoperoxidase, and immunoglobulins of the natural saliva. 7 BioXtra is a new generation of products to relief Xerostomia which includes hydroxyl-ethyl cellulose, xylitol, glucose oxidase, lactoperoxidase, polyglyceryl methacrylate, lactoferrin, lysozyme, monofluorophosphate, and other component of natural saliva. It is introduced in several forms such as spray, mouth wash, gel, toothpaste. 8, 9 Because of lacking study to compare the efficacy of two forms of BioXtra (spray and mouthwash) on radiotherapyinduced Xerostomia, we tried to achieve this goal.
MATERIAlS AND METHODS
Our study was a randomized double blind clinical trial (approved by Ethics Committee of the Research Division of Qazvin University of Medical sciences) and registered on clinical trial. gov: Identifier number: NCT01195233) 20 patients (10 male, 10 female) who were previously subjected to radiotherapy for head and neck cancer at Cancer Institute, Imam Khomeini Hospital, were asked to participate in this study. Coordinator explained the process to each patients and informed consent were signed by them. All the patients agreed to participate. This project was granted approval by Ethics Committee.
Patients with subjective complaint of dry mouth since radiotherapy (≥50Gy) for HNC encompassing bilateral major salivary glands, atleast 6 months earlier were eligible to participate. The age of our patients were 18 years or older. They take nutritious orally (i.e. not parenterally or through PEG tube). Patients with a history of cancer recurrence, end stage malignancies, systemic disease that causes xerostomia such as diabetes mellitus, sjogren syndrome were excluded. Patients, who were taking any medications with anticholinergic side effects such as antidepressants or diuretics, were also excluded.
Using random allocation software, all eligible patients allocated in two groups:
The first group was given BioXtra spray for 2 weeks followed by 1 week wash-out period then, they used BioXtra mouthwash for the next 2 weeks. The order of the interventions was changed for the second group (the first 2 weeks, BioXtra mouthwash and after the washout, BioXtra spray was applied).
During the study, application of other products for the treatment of xerostomia such as saliva substitutes or stimulants was not allowed; although, patients could take sips of water frequently. However, they were permitted to use other mouth care systems such as antifungal treatment or topical analgesic agents.
The clinician who visited the patients during the study was different from the one who gave the intervention to the patients. Data collectors and the one who analyzed the data know the groups only as A or B and they did not know the order of drug usage.
Involved patients were asked to fill out two forms of questionnaire at first visit or day 0. They were also asked to complete two other forms at the second visit (day 14) and the third visit (day 35). Questionnaires which were used was similar to shadad et al 8 Questionnaire for the second and the third visits (day 14 and 35) of treatment Variables recorded based on 100 mm VAS 1. How effective was the product system at relieving your dry mouth? (Extremes: 0 = 'not effective at all', 100 = extremely effective') 2. How pleasant was the taste of the product? (Extremes: 0 = 'not pleasant at all', 100 = 'extremely pleasant') 3. How pleasant did your mouth feel after using the product system? (Extremes: 0 = 'not pleasant at all', 100 = 'extremely pleasant'). We used SPSS vs 18.0 to analyze our data considering level of significance less than 0.05. Statistical analysis between two forms (spray and mouthwash) was done using Student t-test (for VAS scale) and exact fisher test (for dichotomous scale).
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RESUlTS
Our study was performed on 20 patients (10 males and 10 females). Table 1 shows VAS scores recorded for the first question. Mean VAS for each question at first day is reported.
At the beginning of the study, all the patients (100%) were suffering from xerostomia. A total of 19 patients had dryness at night. Getting bad taste in mouth, effect on denture, avoiding speaking was observed in 16 (80%), 4 (20%) and 18 (90%) of the patients, respectively. Five patients (25%) used saliva substitute among them 4 patients (80%) found it useful.
By using both forms of BioXtra (spray and mouthwash), we observed improvement in xerostomia and its complications. Results of application of two systems after 14 days listed in Tables 2 and 3 .
DISCUSSION
We showed that BioXtra products (spray and mouthwash), have significant effects on xerostomia related complications along with better acceptance among patients. Both products have the same effects on alleviating xerostomia complications. Their acceptance among patients is similar. These products have the most effect on improvement of oral dryness and speech with least on patients taste.
Xerostomia is considered as a major side-effect following radiotherapy in the field of head and neck.
1 It can adversely affect patient's quality of life. Oral functions such as ability to sallow, speaking can be violated. Susceptibility to dental caries and oral infections is common among these patients. As a result of impaired lubrication, low tolerance for dental prostheses can be observed. These symptoms can change food choices with subsequent malnutrition. 10, 11 To reduce the severity of oral complications due to xerostomia, aggressive oral care before radiotherapy is recommended. Evaluation of oral health status by a dental team before starting radiotherapy is vital part. Special attention must be given to mucosal lesions, dental caries, periodontal problem and improper dentures. 1 Current management of xerostomia largely relies on the symptomatic treatment. Pharmacologic management include the use of fluoride agents for optimal oral hygiene, antimicrobials to prevent oral infection, saliva substitutes to overcome dryness, and sialogogic agents to stimulate the remaining salivary gland tissues for saliva production. 12, 13 Saliva substitutes containing hydroxyethyl, hydroxypropyl, or CMC may be helpful by temporarily wetting the oral mucosa to overcome complications of xerostomia.
